To amend the Foreign Assistance Act of 1961 to modify treatment activities for assistance to combat HIV/AIDS.

Bill Number: H.R. 4627
Origin Chamber: House
Congress: 119th Congress, Session 1
Policy Area: International Affairs
Status: Introduced
Latest Action: 2025-07-23: Referred to the House Committee on Foreign Affairs.
Last Updated: 2025-09-16T14:04:07Z

AI-Generated Summary

Purpose

This bill, H.R. 4627, aims to update U.S. foreign aid policies for combating HIV/AIDS by expanding and clarifying prevention activities. It modifies the Foreign Assistance Act of 1961 to include new tools like pre-exposure prophylaxis (PrEP) medications—preventive drugs taken by people at high risk of HIV to reduce infection chances—and designates certain prevention efforts as essential "core life-saving humanitarian assistance."

Key Provisions

Amendments to Section 104A(d) of the Foreign Assistance Act (22 U.S.C. 2151b-2(d)):
Paragraph (1): Expands the list of authorized prevention activities to explicitly include providing PrEP medications (new subparagraph (L)). It also adds language stating that these activities "shall be considered to be core life-saving humanitarian assistance," emphasizing their priority in aid programs.
Paragraph (2): Makes minor grammatical adjustments (adding "and" and changing punctuation) to the list of activities, without altering substance.
Paragraph (3)(A): Refines language on targeting "specific populations" to include "at-risk populations" based on scientific analysis from the World Health Organization (WHO). It inserts that prevention efforts to reduce HIV risk are "core life-saving humanitarian assistance," specifically mentioning pre-exposure and post-exposure prophylaxis (preventive treatments before and after potential exposure).

These changes focus on integrating evidence-based prevention strategies into U.S. global HIV/AIDS aid.

Significant Changes to Existing Law

Adds PrEP medications as an explicitly authorized form of assistance, which was not previously listed, broadening the scope of preventive care.
Introduces the designation of HIV prevention activities (including PrEP and targeting at-risk groups per WHO guidelines) as "core life-saving humanitarian assistance." This elevates their status, potentially making them more insulated from budget cuts or policy shifts compared to general aid.
Enhances focus on scientific, WHO-aligned targeting of at-risk populations, shifting from broader "efforts to reduce risk" to more precise, evidence-driven approaches.

Potential Impacts

On Government Agencies: U.S. agencies like the Department of State and USAID, which administer foreign HIV/AIDS aid (e.g., through the President's Emergency Plan for AIDS Relief, or PEPFAR), may see increased flexibility to fund PrEP programs. This could streamline aid allocation but require updates to budgeting and reporting.
On Citizens and International Relations: In recipient countries (primarily in sub-Saharan Africa and other high-prevalence areas), at-risk individuals—such as key populations including men who have sex with men, sex workers, and people who inject drugs—could gain better access to preventive HIV tools, potentially reducing new infections. Globally, it strengthens U.S. leadership in HIV prevention, fostering partnerships with organizations like WHO and improving diplomatic ties through health aid.
Broader Effects: May lower long-term HIV transmission rates in aided nations, easing burdens on local health systems and reducing future aid needs.

Main Stakeholders Affected

U.S. Policymakers and Agencies: Congress (via the Foreign Affairs Committee), State Department, USAID, and PEPFAR coordinators, who implement and fund these programs.
International and Recipient Entities: WHO (for scientific guidance), foreign governments and health ministries in HIV-affected countries, and non-governmental organizations delivering aid on the ground.
Affected Populations: At-risk groups in low- and middle-income countries receiving U.S. aid, including marginalized communities vulnerable to HIV.
Advocacy Groups: HIV/AIDS nonprofits, pharmaceutical companies producing PrEP (e.g., those making drugs like Truvada), and global health advocates pushing for expanded prevention.

Notable Legal, Constitutional, or Political Implications

Legal: Aligns U.S. aid with international standards (e.g., WHO designations), potentially reducing legal challenges to aid programs by emphasizing humanitarian priorities. No direct constitutional issues, as it falls under Congress's authority over foreign appropriations (Article I, Section 8).
Political: Signals bipartisan support for global health (introduced by a diverse group of Democrats), but could spark debates on aid spending amid U.S. budget constraints. By framing prevention as "core humanitarian assistance," it may protect funding from partisan cuts, though it requires congressional approval to take effect.
Other: Promotes equity in HIV prevention by targeting at-risk groups, addressing criticisms of past aid focusing unevenly on treatment over prevention.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Ansari, Yassamin [D-AZ-3]

Cosponsors (17)

Rep. Carson, André [D-IN-7], Rep. Cohen, Steve [D-TN-9], Rep. Evans, Dwight [D-PA-3], Rep. Gottheimer, Josh [D-NJ-5], Rescom. Hernández, Pablo Jose [D-PR-At Large], Rep. Johnson, Henry C. "Hank" [D-GA-4], Rep. Krishnamoorthi, Raja [D-IL-8], Rep. McIver, LaMonica [D-NJ-10], Del. Norton, Eleanor Holmes [D-DC-At Large], Rep. Pocan, Mark [D-WI-2], Rep. Pressley, Ayanna [D-MA-7], Rep. Simon, Lateefah [D-CA-12], Rep. Soto, Darren [D-FL-9], Rep. Thanedar, Shri [D-MI-13], Rep. Tlaib, Rashida [D-MI-12], Rep. Wasserman Schultz, Debbie [D-FL-25], Rep. Watson Coleman, Bonnie [D-NJ-12]

Recent Actions

2025-07-23: Referred to the House Committee on Foreign Affairs.
2025-07-23: Introduced in House
2025-07-23: Introduced in House

Bill Versions

To amend the Foreign Assistance Act of 1961 to modify treatment activities for assistance to combat HIV/AIDS. — issued 2025-07-23 — PDF (3 pages)